
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 15, 2019

MEDOVEX CORP.

(Exact Name of Registrant as Specified in Charter)

Nevada <hr/> (State or other jurisdiction of incorporation)	001-36763 <hr/> (Commission File Number)	46-3312262 <hr/> (IRS Employer Identification No.)
3060 Royal Boulevard S, Ste. 150 Alpharetta, Georgia <hr/> (Address of principal executive offices)		30009 <hr/> (Zip Code)

Registrant's telephone number, including area code: (844) 633-6839

Copies to:

Arthur S. Marcus, Esq
Sichenzia Ross Ference LLP
1185 Avenue of the Americas
37th Floor
New York, New York 10036 (212) 930-9700
(212) 930-9725 (fax)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 5.02 Departure of Directors or Certain Officers; Election of Director; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On February 15, 2019, Dennis Moon resigned from his position as the executive vice president of Medovex Corp., a Nevada company (the "Company"), effective immediately. Mr. Moon resigned from his position at the Company for personal reasons, not as a result of or caused by any disagreements Mr. Moon and the Company on any matter relating to the Company's operations, policies, or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDOVEX CORP.

Date: February 15, 2019

By: /s/ Jeremy Daniel

Jeremy Daniel
Chief Financial Officer
